A significant number of pediatric inflammatory bowel disease patients are exposed to a medication not approved by the Food and Drug Administration for pediatric use
Published August 2025
Rusch C, Perkins AJ, Steiner SJ; ImproveCareNow Pediatric IBD Learning Health System. A significant number of pediatric inflammatory bowel disease patients are exposed to a medication not approved by the Food and Drug Administration for pediatric use. J Pediatr Gastroenterol Nutr. 2025 Nov;81(5):1208-1215. doi: 10.1002/jpn3.70200. Epub 2025 Aug 25. PMID: 40855748; PMCID: PMC12580454.
Therapeutic Drug Monitoring in Pediatric IBD: A Nationwide Survey of Anti-TNF Therapy Practices, Attitudes, and Barriers
Published August 2025
Ruben J Colman, Jennifer L Dotson, Melissa Mock, Kelly Sandberg, Shehzad Saeed, Peter Margolis, Jasbir Dhaliwal, Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease: A Nationwide Survey of Anti-TNF Therapy Practices, Attitudes, and Barriers, Crohn's & Colitis 360, Volume 7, Issue 3, July 2025, otaf050, https://doi.org/10.1093/crocol/otaf050
Proactive therapeutic drug monitoring (TDM) for tumor necrosis factor alpha antagonist (anti-TNF) therapy in adult inflammatory bowel disease (IBD) remains controversial, with inconsistent findings from clinical trials and meta-analyses. Pediatric societal guidelines endorse the implementation of proactive TDM. However, the integration of TDM into clinical practice by pediatric gastroenterologists has not been characterized. This study was undertaken to delineate the practice patterns, attitudes, and barriers associated with anti-TNF TDM among pediatric gastroenterologists across the United States.
Patient and healthcare professional perspectives on fatigue assessment in pediatric inflammatory bowel disease
Published June 2025
David JG, Kamara D, Al-Timimi N, Crabtree VM, Ali S; ImproveCareNow Learning Health System. Patient and healthcare professional perspectives on fatigue assessment in pediatric inflammatory bowel disease. JPGN Rep. 2025 Jul 28;6(4):455-460. doi: 10.1002/jpr3.70068. PMID: 41245025; PMCID: PMC12611615.
Pediatric patients with active and quiescent inflammatory bowel disease (IBD) have known fatigue, but there is limited understanding of how fatigue is clinically assessed. This study explored perspectives of pediatric IBD patients and healthcare professionals (HCPs) regarding fatigue assessments.
Self-Compassion in Adolescents and Young Adults With Inflammatory Bowel Disease: Relationship of Self-Compassion to Psychosocial and Physical Outcomes
Published May 2025
Neiman N, Boothroyd D, Anjur K, Bensen R, Yeh AM, Wren AVA. Self-Compassion in Adolescents and Young Adults With Inflammatory Bowel Disease: Relationship of Self-Compassion to Psychosocial and Physical Outcomes. Inflamm Bowel Dis. 2025 May 12;31(5):1295-1305. doi: 10.1093/ibd/izae170. PMID: 39167919.
Adolescents and young adults (AYAs) diagnosed with inflammatory bowel disease (IBD) are at an increased risk for poor physical and mental health due to the complexity of pediatric onset IBD and the unique developmental challenges of this period of life. Self-compassion is increasingly recognized as having an important role in explaining health outcomes and well-being across a range of populations. This study examines the relationship between self-compassion and psychosocial and physical health outcomes in AYAs with IBD.
Infliximab Biosimilar Utilization in a Large Pediatric Learning Health System
Published May 2025
Maltz RM, Saeed SA, Adler J. Infliximab Biosimilar Utilization in a Large Pediatric Learning Health System. Children (Basel). 2025 May 20;12(5):656. doi: 10.3390/children12050656. PMID: 40426835; PMCID: PMC12110582.
Infliximab biosimilars entered the United States (US) market in November 2016. Uptake of infliximab biosimilars has been slow in adult studies. We aimed to assess variation in the initiation of infliximab biosimilars in a large pediatric cohort.
Multicenter study of continuing ustekinumab after intravenous induction reactions in pediatric Crohn's disease
Published May 2025
Joann Samalik, Andrew Singer, Sabina Ali, Archana Anandakrishnan, Michaella K. Baker, Jana Creps, Camila Khorrami, Ross M. Maltz, Lauren Manning, Jonathan Moses, Brad Pasternak, Perseus V. Patel, Dianne C. Singer, David L. Suskind, Becca Trombler, Jeremy Adler, JPGN Rep. 2025; 6: 451-454. doi:10.1002/jpr3.70065
Reactions to intravenous ustekinumab for inflammatory bowel disease (IBD) occur, the frequency of which is uncertain. It is unclear how often subcutaneous treatment is continued after reactions to the intravenous dose, or how well it is tolerated. We therefore conducted a retrospective cohort study of pediatric patients who initiated ustekinumab for Crohn's disease from 6 pediatric IBD centers in the United States.